Tag: expanded access
Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access
Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations. FDA submission planned as five-year pancreatic cancer survival…
Submit Your Paper to GMJ
No APC until January 2027.